SRP8053

IL-35 (mouse): FC (human)

recombinant, expressed in CHO cells

• Synonym(s): Interleukin-35, T-cell immunoglobulin and mucin domain-containing protein 4
• UNSPSC Code: 12352200
• NACRES: NA.32

Properties

• biological source: human; mouse
• recombinant: expressed in CHO cells
• Assay: ≥98% (SDS-PAGE)
• form: lyophilized
• mol wt: monomer 23 kDa by calculation (IL-12a (p35)); monomer 46 kDa by calculation (Ebi3)
• packaging: pkg of 5 μg
• technique(s): activity assay: suitable
• impurities: <0.06 EU/μg endotoxin, tested
• color: white
• UniProt accession no.: O35228; P43431
• shipped in: wet ice
• storage temp.: −20°C
• Gene Information: mouse ... Ebi3(50498) , Il12a(16159)

Description

General description

Research area: IMMUNO AND CKS. Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs.[1][2]

Application

IL-35 has been used to study its immunosuppressive effect on acute graft-versus-host disease in a mouse model.[3]Ithas also been used to study its effects on the differentiation of granulocytemacrophage-colony-stimulating factor-producing T helper cells (ThGM).[4] IL-35has been used to study its effects on bleomycin-induced pulmonary fibrosis.[5]

Biochem/physiol Actions

Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells′ ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.[1][2]IL-35 is produced inresponse to agonists of toll-like receptors 3 and 4 (TLR 3 & 4) and interferon γ (IFN-γ). It is secreted mainly by activated B cells, CD4⁺ Foxp3⁺ regulatoryT cells (Tregs), and at a lower concentration by monocytes, smooth muscle cells, and endothelial cells.[6]

Physical form

Lyophilized from 0.2 μm-filtered solution in PBS.

Reconstitution

Reconstitute at 100 μg/mL in sterile PBS.

Other Notes

The mouse IL-35 complex composed of the Ebi3 subunit (aa 23-228) and the IL-12a (p35) subunit (aa 23-215) is fused through a polypeptide linker to the Fc region of human IgG1.

Safety Information

• Storage Class Code: 10 - Combustible liquids
• WGK: WGK 2
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable